Vanguard Personalized Indexing Management
TCRX icon

Vanguard Personalized Indexing Management’s TScan Therapeutics TCRX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6K Sell
17,959
-3,400
-16% -$3.62K ﹤0.01% 2211
2026
Q1 		$21.6K Buy
21,359
+6,682
+46% +$7.14K ﹤0.01% 2119
2025
Q4 		$14.7K Sell
14,677
-6,315
-30% -$9.14K ﹤0.01% 1952
2025
Q3 		$38.2K Buy
20,992
+1,100
+6% +$1.95K ﹤0.01% 1932
2025
Q2 		$28.8K Buy
+19,892
New +$28.7K ﹤0.01% 1880

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Vanguard Personalized Indexing Management's TCRX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its TScan Therapeutics (TCRX) stake by 16% in Q2 2026, selling an estimated $3.62K and leaving 17,959 shares worth $17.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2211.

Vanguard Personalized Indexing Management first reported a position in TCRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $38.2K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 17,959 shares of TScan Therapeutics worth $17.6K as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 3,400 TScan Therapeutics shares in Q2 2026, an estimated $3.62K.
  • TScan Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2211 holding.
  • Vanguard Personalized Indexing Management first reported a position in TScan Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Vanguard Personalized Indexing Management's TScan Therapeutics position peaked at $38.2K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.